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INTRODUCTION 
Only 10 to 15% of adrenal incidentalomas are 
classified as hyper-functioning.  Of functional 
tumors, the majority are subclinical Cushing’s 
syndromes, followed by pheochromocytomas 
and  aldosterone producing adenomas.  
Aldosterone and cortisol co-secreting tumors 
are rare. Current clinical practice guidelines 
have limited recommendations regarding the 
evaluation and management of co-secreting 
adenomas. 
 
CASE PRESENTATION:  
 An 86 year old female with long standing, 
resistant hypertension despite a five drug 
regimen, was transferred for management of 
hypertensive emergency.  Due to notable 
hypokalemia on presentation, a work up for 
primary aldosteronism (PA) was pursued with a 
suggestive screening aldosterone-to-renin ratio 
of 38.  PA was confirmed with an elevated 
aldosterone level on a salt loaded 24-hour urine 
collection.  Adrenal imaging revealed a right 
adrenal mass, likely an adrenal adenoma. In 
light of this finding, screening for Cushing’s 
syndrome and pheochromocytoma was 
undertaken to complete the hormonal 
evaluation. Notably, a 24-hour urine free cortisol 
was elevated at 121µg/24hrs with a subsequent 
abnormal overnight dexamethasone 
suppression test confirming a diagnosis of 
subclinical Cushing’s syndrome.  This was 
ACTH independent in etiology confirming an 
adrenal source.  Laparoscopic adrenalectomy 
was pursued with pathology revealing a 4.2 x 
3.1 x 3.0 cm adrenal nodule. The patient did well 
post-operatively requiring only one blood 
pressure agent.  
Figure 1: CT scan of the abdomen without intravenous 
contrast revealing a right adrenal mass, left transverse view 
and right coronal view 
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DISCUSSION 
Primary aldosteronism is a common cause of secondary 
hypertension. Although screening for pheochromocytoma, 
Cushing’s syndrome and PA is recommended for the work up 
of an adrenal incidentaloma, expert guidelines for the 
evaluation of PA do not mandate the same comprehensive 
hormonal evaluation.  Had this screening not been 
undertaken in our patient, a diagnosis of an aldosterone and 
cortisol co-secreting adrenal tumor would have been missed. 
 
Table 1: 
Endocrine Lab 
Evaluation 
Test Result Normal Value 
Aldosterone 23 <22 ng/dl 
Renin 0.6 2.9-10.8 
ng/ml/hr 
PAC/PRA 38 <30 
24 hr UFC  121 3.5-45 µg/ml/hr 
1mg DST 9 < 1.8 µg/dl 
24 hr urinary 
catecholamine 
and 
metanephrine  
Normal 
UFC : Urinary free cortisol 
DST: Dexamethasone suppression test  
Figure 2: Pathology slides, low power (left) and high power (right), 
showing the similarity of the adenoma cells to the non-neoplastic cells 
of the adrenal cortex; the cells are bland, without nuclear 
pleomorphism.  
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